Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
- Author:
Sung Won LEE
1
;
Jonggi CHOI
;
Seung Up KIM
;
Young-Suk LIM
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2021;27(3):402-412
- CountryRepublic of Korea
- Language:English
- Abstract: Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
